



#8/P  
RECEIVED  
6/8/01

JUN 05 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

TECH CENTER 1600/2900

In re application of :  
Klaus STOCKEMANN et al. : Group Art Unit: 1617  
Serial No.: 09/392,728 : Examiner: H. Nguyen  
Filed: September 9, 1999 :  
For: **COMBINATION CONTRACEPTIVE, KITS THAT CONTAIN THE LATTER,  
AND A METHOD THAT USES THE LATTER**

**REPLY**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action dated November 30, 2000, please amend the above-referenced application as indicated below and consider the remarks which follow. (a marked-up version of the claims is attached hereto)

**IN THE CLAIMS:**

Please cancel claim 49 without prejudice or disclaimer.

Please amend claims 5, 10, 11, 24, 25 as indicated below.

AI 5. (Amended) A multi-phase combination preparation of claim 1, wherein the second phase comprises 7 to 14 daily dosage units.

AA 10. (Amended) A multi-phase combination preparation of claim 1, wherein the competitive progesterone antagonist is:

17 $\alpha$ -ethinyl-17 $\beta$ -hydroxy-11 $\beta$ -(4-methoxyphenyl)estra-4,9-dien-3-one,

11 $\beta$ -(4-acetylphenyl)-17 $\beta$ -hydroxy-17 $\alpha$ -(1-propenyl)estra-4,9-dien-3-one,

(Z)-11 $\beta$ -(4-acetylphenyl)-17 $\beta$ -hydroxy-17 $\alpha$ -(3-hydroxy-1-propenyl)estra-4,9-dien-3-

one,

11 $\beta$ -(4-dimethylaminophenyl)-17 $\beta$ -hydroxy-17 $\alpha$ -(1-propenyl)estra-4,9-dien-3-one,